Tegafur-uracil-induced rapid development of advanced hepatic fibrosis

Abstract

Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1.79% of Japanese patients. The development of tegafur-uracil-induced hepatic fibrosis with portal hypertension is rare. Here, we report a case of a 74-year-old woman with rapidly developing tegafur-uracil-induced hepatic fibrosis. The patient had no history of liver disease and had been treated with tegafur-uracil for 8 mo after breast cancer surgery. The patient was admitted to our hospital for abdominal distension and leg edema associated with liver dysfunction. Computed tomography imaging revealed massive ascites and splenomegaly, and a non-invasive assessment of liver fibrosis indicated advanced fibrosis. The histopathological findings revealed periportal fibrosis and bridging fibrosis with septation. The massive ascites resolved after discontinuing tegafur-uracil. These findings suggest that advanced hepatic fibrosis can develop from a relatively short-term administration of tegafur-uracil and that non-invasive assessment is useful for predicting hepatic fibrosis.

Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy

“…It is important to stop anticancer treatment in the event of chemotherapy toxicity, and we should carefully monitor all side effects of chemotherapy. Furthermore, there is a risk of secondary carcinoma due to the long-term administration of chemotherapy (36, 37). Because S-1 is recommended as first-line adjuvant chemotherapy for pancreatic cancer in Japan, we present this case to draw attention to an important side effect associated with its long-term use.…”

Drug resistance mechanism of ns3/4a protease and identification of potent compounds inhibiting reverse transcriptase of hepatitis virus

“…23)) and similarity search for 50% of nucleoside-based scaffold; as a result, only 16 screened compounds were obtained. Subsequently, the anti-HBV, anti-HIV and other drugs, which already tested with HBV (e.g., zidovudine, telbivudine, stavudine, didanosine, tegafur and Isoprinosine) [128][129][130], were removed from such 16 compounds, remaining only 10 drugs left as shown in Table 2. Finally, three of them, including floxuridine (FdU, an anti-cancer drug) [131], trifluridine (TFT, an anti-herpesvirus drug) [132], sofosbuvir (SOF, a high molecular weight drug) [133] were selected as representative compound for in vitro…”